Discussion Guide — Chapter 32

Six prompts, with what to listen for. Each is written to be usable cold, without preparation.

Prompt 1 — "Where did the other 26% go?"

Set up: Establish that a 30-residue peptide at 99% per step is about 74% correct. Then ask the class what the remaining 26% consists of. Do not accept the first answer.

Listen for: - ✅ Someone states that the failed chains kept growing and are still in the vessel. This is the chapter's central mechanical insight and everything else depends on it. - ✅ Someone notices it is not one impurity but many — up to one per position. - ⚠️ "It's waste" / "it fell apart" — the absence model. Push: "Where physically is it? It was on a bead. What happened to that bead on the next cycle?" - ⚠️ "It gets purified out." Ask how, and then bring in the properties table. - ❗ If nobody gets there, do not supply the answer — draw the chain, mark the gap, and ask what happens on the next deprotection. The realization is worth the silence.

Prompt 2 — "Here is a certificate that says 98%. What do you now know?"

Set up: Write only Purity: 98.0% (HPLC) on the board. Ask what the class can conclude.

Listen for: - ✅ "That one peak was 98% of the detected area" — the precise, minimal reading. - ✅ Someone asks what method, what column, what wavelength. That instinct is the transferable skill. - ✅ Someone raises identity: nothing here says the peak is the labeled molecule. - ✅ Someone raises mass: counterion and water are outside the calculation. - ⚠️ "It's 98% pure so 2% is contaminants" — true but uninformative; ask what the 2% is made of and whether it is one thing. - ⚠️ Cynicism ("they're lying"). Redirect firmly: the chapter's position is that the number may be entirely honest and still not answer the reader's question. That is a harder and more useful idea than fraud.

Prompt 3 — "Why couldn't they just make more?"

Set up: Describe the shortage without explaining it. Ask the class to propose the bottleneck, and write every proposal on the board before evaluating any.

Listen for: - ✅ Somebody proposes synthesis, and the class should test it against §32.7's answer — capacity was expanded successfully. - ✅ Somebody reaches the final steps: sterile filling, devices. - ✅ The strongest move: someone asks why money didn't fix it, and answers in terms of validation time rather than capital. - ⚠️ "Artificial scarcity to keep prices high." Take it seriously rather than dismissing it — then ask what evidence would distinguish that hypothesis from the capacity one, and note that the company buying fill-finish sites is evidence against it. - ❗ The teaching point to land: the class's own first instinct (make more of the molecule) is exactly the instinct that makes the gray-market argument feel reasonable. Name that out loud.

Prompt 4 — "Is the position-34 substitution chemistry or biology?"

Set up: Remind the class of Chapter 4: Aib at position 8 blocks DPP-4. Then present position 34 and ask which kind of decision it is.

Listen for: - ✅ Recognition that position 8 is pharmacological and position 34 is a manufacturing fix — two modifications in one molecule, solving different classes of problem. - ✅ Someone articulates why attachment isomers are especially bad: same mass, same composition, so mass spectrometry cannot resolve them. - ✅ The sophisticated version: the two are not exclusive, and the arginine was chosen partly because it preserves charge and therefore activity. Good design solves the process problem without paying a pharmacological price. - ⚠️ "They just tweaked it randomly and this one worked." This is the view the section exists to correct. Ask what a random tweak would have looked like.

Prompt 5 — "Cheaper, or different?"

Set up: State the price comparison neutrally — a prescription product and a research vial, large price gap. Ask what the gap is evidence of.

Listen for: - ✅ Enumeration rather than judgment: fill-finish, formulation, device, cold chain, QC, compliance, evidence, liability. The move from a feeling to a list is the outcome you want. - ✅ Someone states that the gap does not show the molecule is easy to make. - ✅ Someone holds both halves: prescription pricing can be criticized and the price gap is mostly measuring absence. This is the hardest thing in the chapter and the most valuable. - ⚠️ "So the gray market is a rip-off too." Not the claim. Redirect to what is absent, not to who is dishonest. - ⚠️ "So drug companies are justified." Also not the claim; point at Chapter 12. - ❗ Close by reading the chapter's sentence aloud and asking the class to state, in their own words, what it does not say. That inversion is a good exit ticket.

Prompt 6 — "Are these two vials the same?"

Set up: Present two hypothetical vials with identical labels — same name, same stated sequence, same stated mass, same stated purity. Ask what would have to be true for them to be "the same," and write the class's list on the board.

Listen for: - ✅ Items from the dossier list: impurity profile, deletion content, counterion, water, actual peptide mass, sterility, storage history. - ✅ Someone distinguishes the molecule's identity (fixed) from the preparation's identity (not fixed). This is the chapter's thesis in one move. - ✅ Someone points out that for an approved product this question has an enforceable answer, and for the other it has none at all — which is a sharper distinction than "one is better." - ⚠️ "You'd have to test them." Ask for what, and in what order, and what each test leaves open. This is the natural bridge into Chapter 34 and you should take it. - ❗ End the session here. It is the right note: not a verdict about products, but a working list of what a person would need to know — which is what the whole book is trying to build.